Interventional Cardiology: Implantable Cardioverter Defibrillators
Interventional Cardiology: Implantable Cardioverter Defibrillators
$4,750.00
The ICD market alone lost nearly $1bn from $8.3bn in 2019 to $7.4bn in 2020 due to a combination of lockdowns, supply chain disruptions, and logistical strain in the healthcare space. The global market for ICD devices, along with many other medical devices, is currently recovering from a major economic downturn. Therefore, to provide context as to the nature of this market recovery and what exactly it is recovering from, data from 2019 are included. Types of cardiac defibrillators covered by the scope of this report include ICDs, subcutaneous ICDs (S-ICDs), and cardiac resynchronization therapy defibrillators (CRT-Ds). The regions covered by this report are the US, the 5 major European economies (UK, France, Spain, Italy, Germany), Japan, and the rest of the world. The forecast range is 2020-2025.
Author: Pharma Intelligence
Publisher: Meddevicetracker
- Highlights
- Description
- Contents
Highlights
- The market fell from $8.3bn to $7.4bn from 2019 to 2020. The market is making a slow recovery with procedure volumes returning to 2019 levels by 2023.
- In 2020, combined sales of ICDs and CRT-Ds totaled $7421.9m. The largest sales driver was dual chamber ICDs accounting for some 48.1% of total revenue.
- Market drivers include the growing prevalence of cardiovascular disorders in certain regions due to the growing and aging population, and increased buying power in developing economies. Market limiters include trade tariffs, device cost, shortage of doctors with knowledge in implantation, and the ongoing pandemic.
Key topics covered
- This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global markets for implantable cardioverter defibrillators, and cardiac resynchronization therapy defibrillators (CRT-Ds).
The ICD market alone lost nearly $1bn from $8.3bn in 2019 to $7.4bn in 2020 due to a combination of lockdowns, supply chain disruptions, and logistical strain in the healthcare space. The global market for ICD devices, along with many other medical devices, is currently recovering from a major economic downturn. Therefore, to provide context as to the nature of this market recovery and what exactly it is recovering from, data from 2019 are included. Types of cardiac defibrillators covered by the scope of this report include ICDs, subcutaneous ICDs (S-ICDs), and cardiac resynchronization therapy defibrillators (CRT-Ds). The regions covered by this report are the US, the 5 major European economies (UK, France, Spain, Italy, Germany), Japan, and the rest of the world. The forecast range is 2020-2025.
Table of Contents
Executive Summary ………………………………………………………………………. ES-1
i. Cardiac rhythm disorders overview ……………………………………………………………………….. ES-1
ii. Global implantable cardioverter defibrillator products market ………………………………… ES-1
a. Market drivers and limiters ………………………………………………………………………. ES-3
b. Device segment insights ………………………………………………………………………….. ES-5
c. Technology trends …………………………………………………………………………………… ES-5
d. Market leaders ……………………………………………………………………………………….. ES-6
e. Competitive strategies …………………………………………………………………………….. ES-6
f. Emerging competition ……………………………………………………………………………… ES-7
iii. Methodology …………………………………………………………………………………………………….. ES-7
Exhibit ES-1: Global implantable cardioverter defibrillator products market forecast ($m), 2019–25 ……………………………………………………………………………………………………. ES-2
Exhibit ES-2: Global implantable cardioverter defibrillator products market, by country/region, 2020 ……………………………………………………………………………… ES-3
Exhibit ES-3: Drivers and limiters of growth – implantable cardioverter defibrillator products ………………………………………………………………………………….. ES-4
1. Cardiac Rhythm Disorders Overview ………………………………………………. 1-1
1.1 Sick sinus syndrome …………………………………………………………………………………………… 1-4
1.2 Bradycardia ………………………………………………………………………………………………………. 1-4
1.3 Heart block ……………………………………………………………………………………………………….. 1-5
1.4 Tachycardia ………………………………………………………………………………………………………. 1-6
1.5 Atrial fibrillation ………………………………………………………………………………………………… 1-7
1.6 Heart failure ……………………………………………………………………………………………………… 1-9
1.7 Diagnosis and treatment …………………………………………………………………………………… 1-11
1.8 Impact of COVID-19 …………………………………………………………………………………………. 1-11
1.9 Bibliography ……………………………………………………………………………………………………. 1-13
Exhibit 1-1: Estimated prevalence rates of conduction disorders and cardiac arrhythmias, based on healthcare utilization, select countries ………………………………………………………. 1-2
Exhibit 1-2: Estimated number of hospital discharges for conduction disorders and cardiac arrhythmias, select countries ……………………………………………………………………….. 1-3
Exhibit 1-3: Estimated prevalence of atrial fibrillation, select countries, 2021 ………………… 1-8
Exhibit 1-4: Estimated prevalence of chronic heart failure, select countries, 2021 ………….. 1-9
Exhibit 1-5: Estimated prevalence of acute decompensated heart failure, select countries, 2021 ……………………………………………………………………………………………………………….. 1-10
2. Implantable Cardioverter Defibrillator Products ………………………………. 2-1
2.1 Implantable cardioverter defibrillator systems ……………………………………………………… 2-2
2.1.1 Implantable cardioverter defibrillator products ………………………………………. 2-4
2.1.2 Developments in implantable cardioverter defibrillator technology ………….. 2-6
2.2 Bibliography ……………………………………………………………………………………………………… 2-9
Exhibit 2-1: Generic NBD codes for implantable cardioverter defibrillators ……………………. 2-4
Exhibit 2-2: Selected ICDs and manufacturers …………………………………………………………….. 2-5
Exhibit 2-3: Selected CRT-Ds and manufacturers ………………………………………………………… 2-6
3. Implantable Cardioverter Defibrillator Products Market ……………………. 3-1
3.1 Global market insights ……………………………………………………………………………………….. 3-1
3.1.1 Market value ………………………………………………………………………………………. 3-1
3.1.2 Technology trends ………………………………………………………………………………. 3-5
3.1.3 Market drivers and limiters ………………………………………………………………….. 3-6
3.1.4 ICD products overview …………………………………………………………………………. 3-7
3.1.5 Market leaders ………………………………………………………………………………….. 3-10
3.1.6 Competitive strategies ……………………………………………………………………….. 3-10
3.1.7 Emerging competition ……………………………………………………………………….. 3-10
3.2 Global competitors ………………………………………………………………………………………….. 3-11
3.3 Market forecast……………………………………………………………………………………………….. 3-15
3.3.1 Market forecast: US …………………………………………………………………………… 3-15
3.3.2 Market forecast: The five major European markets ……………………………….. 3-19
3.3.3 Market forecast: Japan ………………………………………………………………………. 3-22
3.3.4 Market forecast: rest of the world ………………………………………………………. 3-25
3.4 Bibliography ……………………………………………………………………………………………………. 3-28
Exhibit 3-1: ICD products, global market forecast ($m), 2020–25 ………………………………….. 3-2
Exhibit 3-2: ICD products, global market forecast ($m), by product type, 2020–25 …………. 3-3
Exhibit 3-3: Global ICD products market, share by country/region, 2020 ……………………….. 3-4
Exhibit 3-4: Global ICD product sales, global market forecast ($m), by country/region, 2020–25 …………………………………………………………………………………………………………………. 3-5
Exhibit 3-5: Drivers and limiters of market growth – ICD products ………………………………… 3-7
Exhibit 3-6: ICD products, global market forecast ($m), by product type, 2020–25 …………. 3-9
Exhibit 3-7: Medtronic, revenues by segment ($m), FY2021 ………………………………………. 3-12
Exhibit 3-8: Boston Scientific, revenues by segment, FY2020 ……………………………………… 3-13
Exhibit 3-9: Abbott, revenues by segment, FY2020 ……………………………………………………. 3-14
Exhibit 3-10: Global ICD products market, share by supplier, 2020 ……………………………… 3-15
Exhibit 3-11: US ICD implantations, procedure volumes forecast (000s), 2020–25 ………… 3-17
Exhibit 3-12: US ICD product sales, market forecast ($m), by product type, 2020–25 ……. 3-18
Exhibit 3-13: 5 Euro ICD implantations, procedure volumes forecast (000s), 2020–25 …… 3-20
Exhibit 3-14: 5 Euro ICD product sales, market forecast ($m), by product type, 2020–25 . 3-21
Exhibit 3-14: Japanese ICD implantations, procedure volumes forecast (000s), 2020–25 . 3-23
Exhibit 3-15: Japanese ICD product sales, market forecast ($m), by product type, 2020–25 …………………………………………………………………………………………………… 3-24
Exhibit 3-16: RoW ICD product sales, market forecast ($m), by product type, 2020–25 …. 3-27
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #2 
Sign up to the